Search Results - "Pluzanski, A"

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis by Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

“…First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical…”
Get full text

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial by Borghaei, H, O'Byrne, K J, Paz-Ares, L, Ciuleanu, T-E, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R D, Valette, C A, Brahmer, J R, Reck, M, Ramalingam, S S, Zhang, L, Ntambwe, I, Rabindran, S K, Nathan, F E, Balli, D, Wu, Y-L

“…In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC)…”
Get full text

Platinum-based chemotherapy versus monotherapy in first-line treatment of elderly patients with advanced non-small-cell lung cancer by Pluzanski, A, Piorek, A

Get full text

EGFR tyrosine kinase inhibitors in first-line treatment of elderly patients with advanced non-small-cell lung cancer by Knetki-Wroblewska, M, Pluzanski, A, Krzakowski, M

Get full text

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden by Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

“…Among patients with non–small-cell lung cancer and tumors containing at least 10 mutations per megabase, the 1-year progression-free survival rate was 43% with…”
Get full text

591P The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study by Pluzanski, A., Tysarowski, A., Seliga, K., Gos, A., Zub, R., Krzakowski, M.J.

Get full text

1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations by Janzic, U., Shalata, W., Agbarya, A., Dziadziuszko, R., Szymczak, K., Jakopovic, M., Mountzios, G., Pluzanski, A.

Get full text

1485P Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice by Knetki-Wroblewska, M., Piórek, A., Tabor, S., Winiarczyk, K., Sobczuk, P., Lewandowska, Z., Pluzanski, A., Kowalski, D.M., Krzakowski, M.J.

Get full text

1244P Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT) by Dediu, M., Janzic, U., Marinca, M.V., Pluzanski, A., Turnsek, N., Lupu, R., Teodorescu, G., Donev, I. Shterev

Get full text

1228P Real-world treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT) by Pluzanski, A., Donev, I. Shterev, Gafton, B., Janzic, U., Vidovic, D., Lupu, R., Teodorescu, G., Ciuleanu, T-E.

Get full text

1683P SARS-CoV-2 infection and lung cancer management in Europe by Agbarya, A., Addeo, A., Charpidou, A., Araújo, A., Cuppens, K., Brustugun, O.T., Rajer, M., Jakopovic, M., Marinca, M.V., Pluzanski, A.

Get full text

1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT) by Addeo, A., Hochmair, M.J., Janzic, U., Dudnik, E., Charpidou, A., Pluzanski, A., Ciuleanu, T-E., Donev, I. Shterev, Elbaz, J., Lupu, R., Ott, R.G., Peled, N.

Get full text

HSD57 The Actionable Gaps of the Journey of Patients With Lung Cancer by Chorostowska-Wynimko, J, Barila, R, Jaal, J, Kirova-Nedyalkova, G, Krejci, J, Ostoros, G, Petrova, M, Pluzanski, A, Pop, O, Skrickova, J, Spaks, A, Stanculeanu, DL, Lupu, R, Teodorescu, G, Ryska, A

Get full text

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 by Reck, M., Ciuleanu, T.E., Pluzanski, A., Lee, J.S., Bernabe Caro, R., Linardou, H., Burgers, J., Gallardo, C., Nishio, M., Peters, S., Paz-Ares, L.G., Hellmann, M.D., Borghaei, H., Ramalingam, S.S., O’Byrne, K., Hu, N., Bushong, J., Eccles, L., Grootendorst, D., Brahmer, J.R.

Get full text

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status by Ramalingam, S.S., Balli, D., Ciuleanu, T-E., Pluzanski, A., Lee, J-S., Schenker, M., Bernabe Caro, R., Lee, K.H., Bartolucci, R., Audigier-Valette, C., Hellmann, M.D., Paz-Ares, L.G., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K., Tran, P., Spires, T., Geese, W.J., Agrawal, S.

Get full text

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis by Paz-Ares, L., Ciuleanu, T.E., Yu, X., Salman, P., Pluzanski, A., Nagrial, A., Havel, L., Kowalyszyn, R., Audigier-Valette, C., Wu, Y.-L., Borghaei, H., Hellmann, M.D., Brahmer, J., Reck, M., Ramalingam, S., Zhang, L., Bhagavatheeswaran, P., Nathan, F.E., O'Byrne, K.J.

Get full text

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations by Mok, T.S.K., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Linke, R., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Noonan, K., Tang, Y., Wilner, K.D., Wu, Y.-L.

Get full text

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC by Lind, M., Gettinger, S., Borghaei, H., Brahmer, J., Chow, L., Burgio, M., De Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. Aren, Chiari, R., Butts, C., Wojcik-Tomaszewska, J., Coudert, B., Garassino, M., Ready, N., Felip, E., Garcia, M. Alonso, Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D., Czyzewicz, G., Spigel, D., Crino, L., Eberhardt, W., Li, A., Marimuthu, S., Vokes, E.

Get full text

1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data by Knetki-Wroblewska, M., Płużański, A., Tabor, S., Winiarczyk, K., Zaborowska-Szmit, M., Zajda, K., Janowicz Zebrowska, A., Piórek, A., Badurak, P., Jaśkiewicz, P., Kowalski, D.M., Krzakowski, M.J.

Get full text

PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE by Kawalec, P, Badurak, P, Denisso, T, Jastrzebski, D, Marek, M, Pluzanski, A, Szczesna, A, Szkultecka-Debek, M, Russel-Szymczyk, M

Get full text